PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
204.50
Positive P/E while AVXL shows losses. John Neff would investigate competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
-214.06
Both companies show negative equity. Martin Whitman would check for industry-wide restructuring opportunities.
1843.78
Positive FCF while AVXL shows negative FCF. John Neff would investigate cash generation advantage.
1843.78
Positive operating cash flow while AVXL shows negative OCF. John Neff would investigate operational advantage.
-214.06
Both companies show negative fair values. Martin Whitman would check for industry-wide valuation issues.
0.12%
Positive earnings while AVXL shows losses. John Neff would investigate earnings advantage.
0.05%
Positive FCF while AVXL shows negative FCF. John Neff would investigate cash generation advantage.